PALO ALTO, Calif. – May 31, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced its participation at the Jefferies 2012 Global Healthcare Conference to be held June 4-7 in New York.
David Levison, the company’s president and CEO, will provide an overview of CardioDx and of Corus® CAD, the first and only clinically validated gene expression test for obstructive coronary artery disease. The presentation will take place on Thursday, June 7 at 8:30 a.m. ET at the Grand Hyatt.
With a simple blood draw, Corus CAD can help primary care clinicians and cardiologists exclude obstructive coronary artery disease as the cause of a stable non-diabetic patient's symptoms. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test is safe and does not expose patients to radiation risks or imaging agent intolerance.
Corus CAD has been recognized by The Wall Street Journal’s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME’s Top Ten Medical Breakthroughs.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit http://www.cardiodx.com.
Media Contact: Nicole Osmer